Abbott Gmbh & Co Kg

Basf Aktiengesellschaft

Abbvie Deutschland Gmbh and Co Kg

Abbott Laboratories Corporation

Roland Grandel

Wilfried Martin Braje

Karla Drescher

Andreas Haupt

Liliane Unger

Sean Colm Turner

Wilfried Lubisch

Michael Kock

Sabine Schult

Reinhold Mueller

Udo Lange

Herve Geneste

Daryl Richard Sauer

Christophe Henry

Thomas Hoeger

Hervé Geneste

Gisela Backfisch

Armin Beyerbach

Uta Holzenkamp

Wolfgang Wernet

Thomas Subkowski

Dorothea Starck

Thomas Hoger

Thomas Höger

Thomas H&ouml;ger

Margaretha Bakker

Ana Lucia Jongen-Relo

Reinhold Müller

Michael Vierling

Hans-Jürgen Teschendorf

Wilfried Lubish

Reinhold M&uuml;ller

Dan Plata

The present invention relates to aromatic compounds of the formula I wherein Ar is phenyl or an aromatic 5- or 6-membered C-bound heteroaromatic radical, wherein Ar may carry 1 radical Rand wherein Ar may also carry 1 or 2 radicals R; The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.

Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor

The invention relates to compounds of the formula (I) wherein the variables have meanings given in the claims and the description. The invention also relates to the use of a compound of the formula (I) or a pharmaceutically acceptable salt thereof for preparing a medicament for the treatment of a medical disorder susceptible to the treatment with a 5HTreceptor ligand. 

Heterocyclic arylsulphones suitable for treating disorders that respond to modulation of the serotonin 5HT6 receptor

The invention relates to compounds of the formula (I) wherein the variables have meanings given in the claims and the description. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a medicament for the treatment of a medical disorder susceptible to the treatment with a 5HTreceptor ligand.

Heterocyclic compounds suitable for treating disorders that respond to modulation of the serotonin 5HT6 receptor

The present invention relates to an aminomethyl substituted bicyclic aromatic compound of the formula I  The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine Dreceptor ligand.

[object Object]

The invention related to N-[(piperazinyl)hetaryl]arylsulfonamide compounds of the general formula (I) in which Q is a bivalent, 6-membered heteroaromatic radical which possesses 1 or 2 N atoms as ring members and which optionally carries one or two substituents Rwhich is/are selected, independently of each other, from halogen, CN, NO, COR, COR, C-C-alkyl and C-C-haloalkyl; Ar is phenyl or a 6-membered heteroaromatic radical which possesses 1 or 2 N atoms as ring members and which optionally carries one or two substituents R, which is/are selected from halogen, NO, CN, COR, COR, C-C-alkyl, C-C-alkenyl, C-C-alkynyl, C-C-cycloalkyl, C-C-cycloalkyl-C-C-alkyl and C-C-haloalkyl, with it also being possible for two radicals Rwhich are bonded to adjacent C atoms of Ar to be together C-C-alkylene; Ris hydrogen, C-C-alkyl, C-C-haloalkyl, C-C-cycloalkyl, C-C-cycloalkyl-C-C-alkyl, C-C-hydroxyalkyl, C-C-alkoxy-C-C-alkyl, C-C-alkenyl or C-C-alkynyl; with the radicals n, R, R, R, Rand Rhaving the meanings given in the patent claims, to the N-oxides and to the physiologically tolerated acid addition salts of these compounds and to pharmaceutical compositions which comprise at least one N-[(piperazinyl)hetaryl]arylsulfonamide compound as claimed in one of claimstoand/or at least one physiologically tolerated acid addition salt of I and/or an N-oxide of I, where appropriate together with physiologically acceptable carriers and/or auxiliary substances for treating diseases which respond to influencing by dopamine Dreceptor antagonists or agonists, in particular for treating diseases of the central nervous system and disturbances of kidney function. 

N-[piperazinyl hetaryl]arylsufonamide compounds with affinity for the dopamine D3 receptor

The invention relates to compounds of the formula (I) wherein n is 0, 1 or 2; G is CHor CHR; Ris H, C,-C-alkyl, C,-C-alkyl substituted by C-C-cycloalkyl, C-C-hydroxyalkyl, fluorinated C,-C-alkyl, C-C-cycloalkyl, fluorinated C-C-cycloalkyl, C-Calkenyl, fluorinated C-C-alkenyl, formyl, acetyl or propionyl; R, Rand Rare, independently of each other, H, methyl, fluoromethyl, difluoromethyl, or trifluoromethyl; A is phenylene, pyridylene, pyrimidylene, pyrazinylene, pyridazinylene or thiophenylene, which can be substituted by one or more substituents selected from halogen, methyl, methoxy and CF; E is NRor CH, wherein Ris H or C-C-alkyl; Ar is a cyclic radical selected from the group consisting of phenyl, a 5- or 6-membered heteroaromatic radical comprising as ring members 1, 2 or 3 heteroatoms selected from N, O and S and a phenyl ring fused to a saturated or unsaturated 5- or 6-membered carbocyclic or heterocyclic ring, where the heterocyclic ring comprises as ring members 1, 2 or 3 heteroatoms selected from N, O and S and/or 1, 2 or 3 heteroatom-containing groups each independently selected from NR, where Ris H, C-C-alkyl, fluorinated C-C-alkyl, C-Calkylcarbonyl or fluorinated C-C-alkylcarbonyl, and where the cyclic radical Ar may carry 1, 2 or 3 substituents R, wherein the variable Rhas the meanings given in the claims and in the description; and physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand. 

Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor

The present invention relates to aryloxyethylamine compounds of the formula I and the physiologically tolerated acid addition salts thereof. The variables have the meanings given in the claims and the description. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.

Aryloxyethylamine compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor

Aminoethylaromatic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor

The invention relates to tetrahydrobenzazepines of the general formula I in which the variables Ar, A, B, Y, Rand Rhave the meanings indicated in claim, as well as the N-oxides of these compounds, the physiologically tolerated acid addition salts of these compounds and the physiologically tolerated acid addition salts of the N-oxides. The invention also relates to a pharmaceutical composition that comprises at least one tetrahydrobenzazepine compound of the formula I, the physically tolerated acid addition salt of I, the N-oxide of compound of the formula I and/or the physically tolerated acid addition salts of the N-oxides of I, and further to the use of a compound according to the present invention for treating disorders that respond beneficially to dopamine Dreceptor antagonists or dopamine Dagonists. The compounds according to the invention are preferably useful for the treatment of disorders of the central nervous system such as schizophrenia and depression and for the treatment of renal function disorders.

The present invention relates to novel 4-piperazinylpyrimidine compounds. The compounds possess valuable therapeutic properties and are suitable, in particular, for treating diseases that respond to modulation of the dopamine Dreceptor. The 4-piperzinylpyrimidine compounds have the general formula I wherein Ar, X, A, Rand Rare as defined in the claims.

Disclosed are pyridazine compounds of the formula I which are useful for inhibiting glycogen synthase kinase 3 (GSK-3), methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds: In formula Iindicates a single bond or a double bond;

Pyridazine compounds as glycogen synthase kinase 3 inhibitors

The invention relates to compounds of the formula (I). The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.

The present invention relates to a compound of the formula (I)  The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.

Azabicycloheptyl compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor

The present invention relates to 6-amino(aza)indane compound of the formula (I) Wherein Ar is phenyl or an aromatic 5- or 6-membered C-bound heteroaromatic radical, wherein Ar may carry 1 radical Rand wherein Ar may also carry I or 2 radicals R; X is N or CH; E is CRRor NR; Ris C-C-alkyl, C-C4-cycloalkyl, C-C-cycloalkylmethyl, C-C-alkenyl, fluorinated C-C-alkyl, fluorinated C-C-cycloalkyl, fluorinated C-C-cycloalkylmethyl, fluorinated C-C-alkenyl, formyl or C-C-alkylcarbonyl; Ris H or Rand Ror Rand Rtogether are (CH)with n being 1, 2, 3 or 4; Rand Reach independently are H, CH, CHF, CHFor CF; Ris H or C,-C4-alkyl; and the physiologically tolerated acid addition salts of these compounds. The invention also relates to pharmaceutical compositions comprising at least one compound of the formula (I) or a pharmaceutically acceptable salt thereof and to a method for treating a medical disorder susceptible to treatment with a dopamine D3 receptor ligand, said method comprising administering an effective amount of at least one compound of the formula (I) or a pharmaceutically acceptable salt thereof. 

The invention relates to N-[(piperazinyl)hetaryl]arylsulfonamide compounds of the general formula I in which

Growing community of inventors

Dossenheim, Germany

Roland Grandel